Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT

Main Article Content

Mark Lebwohl
Kim Papp
Benjamin Ehst
Mark Lomaga
Phoebe Rich
Bruce Strober
April Armstrong
José M. López Pinto
Markus Kaspar
Delphine Deherder
Maggie Wang
Ronald Vender

Keywords

Bimekizumab, Psoriasis, Efficacy, Safety, Quality of life, Clinical trial, Long-term, BE RADIANT

Abstract

      


 

References

1. Yeung H et al. J Am Acad Dermatol 2013;68:64–72

2. Schmitt-Egenolf M et al. Dermatol Ther (Heidelb) 2021;11:2107–21

3. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884

4. Hongbo Y et al. J Invest Dermatol 2005;125:659–64

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>